Search Results - "Vera, Moin"
-
1
Immune-Mediated Inflammation May Contribute to the Pathogenesis of Cardiovascular Disease in Mucopolysaccharidosis Type I
Published in PloS one (17-03-2016)“…Cardiovascular disease, a progressive manifestation of α-L-iduronidase deficiency or mucopolysaccharidosis type I, continues in patients both untreated and…”
Get full text
Journal Article -
2
Combining angiotensin receptor blockade and enzyme replacement therapy for vascular disease in mucopolysaccharidosis type I
Published in Molecular genetics and metabolism reports (01-03-2024)“…Vascular involvement in the genetic disorder mucopolysaccharidosis type I (MPS I) has features of atherosclerotic disease near branch points of arterial…”
Get full text
Journal Article -
3
Pentosan Polysulfate: Oral Versus Subcutaneous Injection in Mucopolysaccharidosis Type I Dogs
Published in PloS one (11-04-2016)“…We previously demonstrated the therapeutic benefits of pentosan polysulfate (PPS) in a rat model of mucopolysaccharidosis (MPS) type VI. Reduction of…”
Get full text
Journal Article -
4
Evaluation of non-reducing end pathologic glycosaminoglycan detection method for monitoring therapeutic response to enzyme replacement therapy in human mucopolysaccharidosis I
Published in Molecular genetics and metabolism (01-02-2020)“…Therapeutic development and monitoring require demonstration of effects on disease phenotype. However, due to the complexity of measuring clinically-relevant…”
Get full text
Journal Article -
5
Biochemical Studies in Fibroblasts to Interpret Variants of Unknown Significance in the ABCD1 Gene
Published in Genes (30-11-2021)“…Due to newborn screening for X-linked adrenoleukodystrophy (ALD), and the use of exome sequencing in clinical practice, the detection of variants of unknown…”
Get full text
Journal Article -
6
Specific antibody titer alters the effectiveness of intrathecal enzyme replacement therapy in canine mucopolysaccharidosis I
Published in Molecular genetics and metabolism (01-05-2012)“…Intrathecal enzyme replacement therapy is an experimental option to treat central nervous system disease due to lysosomal storage. Previous work shows that MPS…”
Get full text
Journal Article -
7
A Humoral Immune Response Alters the Distribution of Enzyme Replacement Therapy in Murine Mucopolysaccharidosis Type I
Published in Molecular therapy. Methods & clinical development (16-03-2018)“…Antibodies against recombinant proteins can significantly reduce their effectiveness in unanticipated ways. We evaluated the humoral response of mice with the…”
Get full text
Journal Article -
8
IRF2BPL Is Associated with Neurological Phenotypes
Published in American journal of human genetics (02-08-2018)“…Interferon regulatory factor 2 binding protein-like (IRF2BPL) encodes a member of the IRF2BP family of transcriptional regulators. Currently the biological…”
Get full text
Journal Article -
9
IRF2BPL Is Associated with Neurological Phenotypes
Published in American journal of human genetics (06-09-2018)Get full text
Journal Article -
10
Immune response to intrathecal enzyme replacement therapy in mucopolysaccharidosis I patients
Published in Pediatric research (01-12-2013)“…Background: Intrathecal (IT) enzyme replacement therapy with recombinant human α- L -iduronidase (rhIDU) has been studied to treat glycosaminoglycan storage in…”
Get full text
Journal Article -
11
m.3685T > C is a novel mitochondrial DNA variant that causes Leigh syndrome
Published in Cold Spring Harbor molecular case studies (01-02-2022)“…Variants in the mitochondrial genome can result in dysfunction of Complex I within the electron transport chain, thus causing disruptions in oxidative…”
Get full text
Journal Article -
12
430. Antibodies to Recombinant Human α-L-Iduronidase Enhance Uptake into Macrophages in Murine Mucopolysaccharidosis Type I
Published in Molecular therapy (01-05-2016)Get full text
Journal Article -
13
-
14
Innate immune system activation in MPS I canine vascular disease
Published in Molecular genetics and metabolism (01-02-2014)Get full text
Journal Article -
15
Pentosan polysulfate: New mechanistic insights and treatment of the mucopolysaccharidoses
Published in Molecular genetics and metabolism (01-02-2015)Get full text
Journal Article -
16
-
17
-
18
Immune response to intrathecal enzyme therapy in Mucopolysaccharidosis I patients
Published in Molecular genetics and metabolism (01-02-2011)Get full text
Journal Article -
19
Immune-Mediated Inflammation May Contribute to the Pathogenesis of Cardiovascular Disease in Mucopolysaccharidosis Type I: e0150850
Published in PloS one (01-03-2016)“…Background Cardiovascular disease, a progressive manifestation of [alpha] -L-iduronidase deficiency or mucopolysaccharidosis type I, continues in patients both…”
Get full text
Journal Article -
20
Mannose 6-Phosphate Conjugation Is Not Sufficient to Allow Induction of Immune Tolerance to Phenylalanine Ammonia-Lyase in Dogs
Published in JIMD Reports - Case and Research Reports, 2012/5 (01-01-2013)“…The immune response to exogenous protein has been shown to reduce therapeutic efficacy in animal models of enzyme replacement therapy. A previously published…”
Get full text
Book Chapter Journal Article